Market Intelligence Signals
Thread 5 — Oncology US market · disruption & risk signals with feature explainability
191 drug × indication signals
66 high disruption signals
Updated 2026-07-19
What this page is — and is not
This week's analysis
Model Review Agent · 2026-07-19
Overview

This week's prediction models run with only 5 of 9 features populated (55.6% completeness) — NIH funding momentum, publication velocity, CMS spend trajectory, and patent cliff proximity are all null. The approval model (CV AUC 0.86) is technically informative but practically a single-feature classifier: regulatory momentum (FDA approval count) drives 96% of predictions, with shortage risk as a minor secondary signal. The disruption model similarly reduces to approval-count × shortage-risk. Three edges of interest align well with model output (Bortezomib/MM, Nivolumab/NSCLC), but three others (Keytruda/NSCLC, Opdivo/Melanoma, Venclexta/AML) show near-zero scores because the feature pipeline failed to populate approval counts for brand-name drug node IDs — a data integration bug to fix before next cycle.

Model quality
approval model informativeTrue
approval cv auc0.8635
approval label balance okTrue
approval dominant featureregulatory_momentum_approval_count
approval quality noteCV AUC of 0.86 is misleading — regulatory_momentum_approval_count is the top driver for 184 of 191 predictions (96.3%), making this effectively a single-feature threshold model dressed up with negligible contributions from shortage_risk_score and pipeline_density.
disruption model informativeTrue
disruption quality noteOnly two features have non-zero permutation importance (regulatory_momentum=0.276, shortage_risk=0.221). Pipeline density, policy risk, and trial anomaly contribute nothing. The disruption score is essentially an approval-count × shortage-count product — useful but narrow.
revenue model noteCMS Part D data has a 2-year publication lag. Revenue trajectory index is directional only and should not be used for budgeting or sizing. The CMS spend feature is null for all 191 rows this cycle, so the revenue model is driven entirely by regulatory_momentum and pipeline_density.
Notable signals this week
AKEEGA Prostate Cancer approval probability 100.0% Perfect approval score driven by regulatory_momentum=10 (abiraterone has many formulation/indication approvals). Pipeline density is only 2 trials — model cannot distinguish between drugs with many past approvals and genuine forward-looking expansion potential.
LENALIDOMIDE Multiple Myeloma approval probability 100.0% Score of 1.0 with 10 prior approvals and 17 active trials. Plausible given lenalidomide's established MM dominance, but the model offers no incremental signal beyond 'drug has many approvals'.
BORTEZOMIB Multiple Myeloma disruption risk score 99.8% Highest disruption score — driven by 9 approvals + shortage_risk=2 (Class I/II recalls). Aligns with EOI-002 which flagged biosimilar pressure. This is the model's strongest signal this week.
OPDIVO QVANTIG Non-Small Cell Lung Cancer disruption risk score 99.8% High disruption from 5 approvals + shortage_risk=2. Aligns with EOI-003 which flagged BMS recall + trial sponsorship convergence.
AVASTIN Renal Cell Carcinoma approval probability 3.9% Very low approval probability (0.039) — but EOI-001 flagged this pair for pipeline repositioning signal (40+ new academic RCC publications). The model misses this because publication_velocity_cagr is null. This is a false negative caused by missing feature data.
Feature improvement proposals (3)
nih funding momentum usd per yr low

Currently null for all 191 rows. Tier 2 commit log shows 6 proposals were committed this week to fill this via NIH Reporter v2, but the feature matrix was generated before the commits landed. Re-run feature engineering after Tier 2 commits are applied to the KG to populate this feature. Source: NIH Reporter v2 API (https://api.reporter.nih.gov/).

publication velocity cagr low

Currently null for all 191 rows. Tier 2 commit log shows 6 proposals committed this week. Same timing issue as NIH funding. Re-running the feature pipeline post-commit should populate this. Source: PubMed E-utilities (https://www.ncbi.nlm.nih.gov/books/NBK25501/).

patent cliff proximity yrs medium

Currently null for all 191 rows and no Tier 2 proposal was committed this week. FDA Orange Book data files (https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files) provide patent expiry dates. Adding this would give the approval model a second meaningful signal beyond regulatory_momentum, since drugs near patent expiry face different competitive dynamics. Requires a one-time download and parsing of the Orange Book CSV.

191
Drug × indication signals
66
High disruption (≥60%)
191
Training rows (in-sample)
Yes
Disruption RF trained
Model details & data freshness
Data freshness by vertical
VerticalSourceCadence
Academic research PubMed · NIH Reporter weekly
Drug discovery ChEMBL · Open Targets weekly
Trials Thread 2 cross-ref daily
FDA regulatory openFDA Drugs@FDA weekly
Sales (CMS) CMS Part D 2yr lag — amber always
Manufacturing openFDA enforcement weekly
Distribution HRSA 340B weekly
Government policy Fed Register · Congress weekly
Model metadata
Approval rank (relative — not calibrated)
LogisticRegression(C=1.0, L2)
Label = 1 if drug has any approval post-2018, 0 otherwise. In-sample split — not an external held-out dataset. CV AUC is indicative only.
Disruption risk
RandomForestClassifier(n_estimators=50, max_depth=4)
Labels constructed from observable KG signals (shortage + competitive entry). No validated ground truth.
Revenue trajectory index
Ridge(alpha=1.0)
CMS Part D data has 2yr lag. Treat output as directional index only.
Market entry timing
Empirical approval year distribution per indication
Distribution of approval years, not trial duration. Trial start dates not yet in KG.
Filter:
Signal table — sorted by disruption risk

Click any row to expand feature contributions. Hover evidence column header for tooltip. — in raw features = null (score reliability reduced).

Drug ↕ Indication ↕ Disruption risk ↕ Appr. rank (rel.) ⓘ ↕ Revenue index ↕ Approval yr (median) ↕ Data completeness ⓘ ↕
AKEEGA
ABIRATERONE ACETATE
 Prostate Cancer 99.1% 100.0%
100.0–100.0%
 9.96 2022 (n=33) 56% ▸
AKEEGA
ABIRATERONE ACETATE
 Ovarian Cancer 92.6% 100.0%
100.0–100.0%
 9.96 2022 (n=37) 56% ▸
LENALIDOMIDE
 Chronic Lymphocytic Leukemia 97.3% 100.0%
100.0–100.0%
 9.96 2023 (n=21) 56% ▸
LENALIDOMIDE
 Diffuse Large B-Cell Lymphoma 95.3% 100.0%
100.0–100.0%
 9.96 2023 (n=15) 56% ▸
LENALIDOMIDE
 Multiple Myeloma 96.5% 100.0%
100.0–100.0%
 9.96 2022 (n=28) 56% ▸
BORTEZOMIB
 Multiple Myeloma 99.8% 100.0%
100.0–100.0%
 8.96 2022 (n=28) 56% ▸
DOCETAXEL
 Prostate Cancer 99.1% 100.0%
100.0–100.0%
 9.96 2022 (n=33) 56% ▸
DOCETAXEL
 Gastric Cancer 94.1% 100.0%
100.0–100.0%
 9.96 2022 (n=62) 56% ▸
DOCETAXEL
 Non-Small Cell Lung Cancer 91.7% 100.0%
100.0–100.0%
 9.96 2020 (n=46) 56% ▸
DOCETAXEL
 Breast Cancer 92.9% 100.0%
100.0–100.0%
 9.96 2023 (n=64) 56% ▸
DOCETAXEL
 Head and Neck Cancer 96.3% 100.0%
100.0–100.0%
 9.96 2022 (n=25) 56% ▸
GEMCITABINE HYDROCHLORIDE
 Pancreatic Cancer 99.1% 100.0%
100.0–100.0%
 9.96 2019 (n=10) 56% ▸
GEMCITABINE HYDROCHLORIDE
 Bladder Cancer 96.5% 100.0%
100.0–100.0%
 9.96 2019 (n=15) 56% ▸
GEMCITABINE HYDROCHLORIDE
 Non-Small Cell Lung Cancer 91.7% 100.0%
100.0–100.0%
 9.96 2020 (n=46) 56% ▸
GEMCITABINE HYDROCHLORIDE
 Ovarian Cancer 92.6% 100.0%
100.0–100.0%
 9.96 2022 (n=37) 56% ▸
CAPECITABINE
 Breast Cancer 92.9% 100.0%
100.0–100.0%
 9.96 2023 (n=64) 56% ▸
CAPECITABINE
 Gastric Cancer 94.1% 100.0%
100.0–100.0%
 9.96 2022 (n=62) 56% ▸
CAPECITABINE
 Colorectal Cancer 93.2% 100.0%
100.0–100.0%
 9.96 2022 (n=44) 56% ▸
TOLAK
FLUOROURACIL
 Breast Cancer 92.9% 100.0%
100.0–100.0%
 6.97 2023 (n=64) 56% ▸
TOLAK
FLUOROURACIL
 Head and Neck Cancer 96.3% 100.0%
100.0–100.0%
 6.98 2022 (n=25) 56% ▸
TOLAK
FLUOROURACIL
 Gastric Cancer 94.1% 100.0%
100.0–100.0%
 6.98 2022 (n=62) 56% ▸
TOLAK
FLUOROURACIL
 Colorectal Cancer 93.2% 100.0%
100.0–100.0%
 6.98 2022 (n=44) 56% ▸
CABAZITAXEL
 Prostate Cancer 99.1% 100.0%
100.0–100.0%
 6.98 2022 (n=33) 56% ▸
PACLITAXEL
 Breast Cancer 92.9% 100.0%
100.0–100.0%
 5.98 2023 (n=64) 56% ▸
PACLITAXEL
 Non-Small Cell Lung Cancer 91.7% 100.0%
99.9–100.0%
 5.98 2020 (n=46) 56% ▸
PACLITAXEL
 Ovarian Cancer 92.6% 100.0%
99.9–100.0%
 5.98 2022 (n=37) 56% ▸
PACLITAXEL
 Gastric Cancer 94.1% 100.0%
99.9–100.0%
 5.98 2022 (n=62) 56% ▸
IRINOTECAN HYDROCHLORIDE
 Colorectal Cancer 93.2% 100.0%
99.9–100.0%
 5.98 2022 (n=44) 56% ▸
ENZALUTAMIDE
 Prostate Cancer 99.1% 99.9%
99.9–100.0%
 5.98 2022 (n=33) 56% ▸
OXALIPLATIN
 Colorectal Cancer 93.2% 99.8%
99.8–99.9%
 4.99 2022 (n=44) 56% ▸
OXALIPLATIN
 Gastric Cancer 94.1% 99.8%
99.8–99.9%
 4.99 2022 (n=62) 56% ▸
OPDIVO QVANTIG
NIVOLUMAB
 Non-Small Cell Lung Cancer 99.8% 99.8%
99.7–99.8%
 4.99 2020 (n=46) 56% ▸
OPDIVO QVANTIG
NIVOLUMAB
 Gastric Cancer 99.8% 99.8%
99.7–99.8%
 4.99 2022 (n=62) 56% ▸
OPDIVO QVANTIG
NIVOLUMAB
 Colorectal Cancer 99.8% 99.8%
99.7–99.8%
 4.99 2022 (n=44) 56% ▸
CARFILZOMIB
 Multiple Myeloma 99.8% 99.8%
99.7–99.8%
 4.99 2022 (n=28) 56% ▸
OPDIVO QVANTIG
NIVOLUMAB
 Hepatocellular Carcinoma 99.8% 99.7%
99.7–99.8%
 4.99 2022 (n=14) 56% ▸
OPDIVO QVANTIG
NIVOLUMAB
 Head and Neck Cancer 98.9% 99.7%
99.7–99.8%
 4.99 2022 (n=25) 56% ▸
OPDIVO QVANTIG
NIVOLUMAB
 Melanoma 97.3% 99.7%
99.7–99.8%
 4.99 2024 (n=8) 56% ▸
OPDIVO QVANTIG
NIVOLUMAB
 Renal Cell Carcinoma 99.0% 99.7%
99.6–99.8%
 4.99 2022 (n=13) 56% ▸
IMBRUVICA
IBRUTINIB
 Chronic Lymphocytic Leukemia 93.3% 99.2%
99.0–99.4%
 3.99 2023 (n=21) 56% ▸
PALBOCICLIB
 Breast Cancer 64.9% 98.4%
98.0–98.8%
 2.99 2023 (n=64) 56% ▸
VERZENIO
ABEMACICLIB
 Breast Cancer 22.2% 94.5%
93.2–95.8%
 2.00 2023 (n=64) 56% ▸
LYNPARZA
OLAPARIB
 Breast Cancer 22.2% 94.5%
93.0–95.7%
 2.00 2023 (n=64) 56% ▸
KEYTRUDA
PEMBROLIZUMAB
 Breast Cancer 87.1% 93.5%
91.7–94.8%
 2.00 2023 (n=64) 56% ▸
VENCLEXTA
VENETOCLAX
 Acute Myeloid Leukemia 19.6% 91.7%
89.3–93.3%
 2.00 2026 (n=2) 56% ▸
LYNPARZA
OLAPARIB
 Ovarian Cancer 14.9% 91.4%
89.1–92.9%
 2.00 2022 (n=37) 56% ▸
ZEJULA
NIRAPARIB TOSYLATE
 Ovarian Cancer 14.9% 91.4%
89.0–93.0%
 2.00 2022 (n=37) 56% ▸
KEYTRUDA
PEMBROLIZUMAB
 Non-Small Cell Lung Cancer 99.4% 90.9%
88.7–92.9%
 2.00 2020 (n=46) 56% ▸
TECENTRIQ
ATEZOLIZUMAB
 Non-Small Cell Lung Cancer 99.4% 90.9%
88.3–92.8%
 2.00 2020 (n=46) 56% ▸
VENCLEXTA
VENETOCLAX
 Chronic Lymphocytic Leukemia 15.6% 90.8%
88.2–92.7%
 2.00 2023 (n=21) 56% ▸
KEYTRUDA
PEMBROLIZUMAB
 Colorectal Cancer 99.4% 90.6%
88.4–92.9%
 2.00 2022 (n=44) 56% ▸
KEYTRUDA
PEMBROLIZUMAB
 Gastric Cancer 99.4% 90.5%
88.3–92.7%
 2.00 2022 (n=62) 56% ▸
KEYTRUDA
PEMBROLIZUMAB
 Bladder Cancer 99.4% 90.5%
87.7–92.4%
 2.00 2019 (n=15) 56% ▸
TECENTRIQ
ATEZOLIZUMAB
 Bladder Cancer 99.4% 90.5%
88.5–92.4%
 2.00 2019 (n=15) 56% ▸
KEYTRUDA
PEMBROLIZUMAB
 Hepatocellular Carcinoma 99.4% 90.4%
87.9–92.5%
 2.00 2022 (n=14) 56% ▸
KEYTRUDA
PEMBROLIZUMAB
 Melanoma 95.9% 90.2%
87.7–92.2%
 2.00 2024 (n=8) 56% ▸
KEYTRUDA
PEMBROLIZUMAB
 Head and Neck Cancer 97.2% 90.1%
87.9–92.1%
 2.00 2022 (n=25) 56% ▸
RITUXAN
RITUXIMAB
 Diffuse Large B-Cell Lymphoma 94.2% 89.4%
86.6–91.7%
 2.00 2023 (n=15) 56% ▸
RITUXAN
RITUXIMAB
 Chronic Lymphocytic Leukemia 94.2% 89.2%
86.7–91.3%
 2.00 2023 (n=21) 56% ▸
KADCYLA
ADO-TRASTUZUMAB EMTANSINE
 Breast Cancer 3.8% 82.3%
78.1–86.0%
 1.00 2023 (n=64) 56% ▸
KANJINTI
TRASTUZUMAB-ANNS
 Breast Cancer 3.8% 82.3%
78.8–85.6%
 1.00 2023 (n=64) 56% ▸
OGIVRI
TRASTUZUMAB-DKST
 Breast Cancer 3.8% 82.3%
78.0–85.1%
 1.00 2023 (n=64) 56% ▸
TRAZIMERA
TRASTUZUMAB-QYYP
 Breast Cancer 3.8% 82.3%
78.2–85.8%
 1.00 2023 (n=64) 56% ▸
HERCESSI
TRASTUZUMAB-STRF
 Breast Cancer 3.8% 82.3%
78.5–85.8%
 1.00 2023 (n=64) 56% ▸
HERZUMA
TRASTUZUMAB-PKRB
 Breast Cancer 3.8% 82.3%
78.6–85.7%
 1.00 2023 (n=64) 56% ▸
ONTRUZANT
TRASTUZUMAB-DTTB
 Breast Cancer 3.8% 82.3%
78.5–85.6%
 1.00 2023 (n=64) 56% ▸
HERCEPTIN HYLECTA
TRASTUZUMAB AND HYALURONIDASE-OYSK
 Breast Cancer 3.8% 82.3%
78.1–85.6%
 1.00 2023 (n=64) 56% ▸
ENHERTU
FAM-TRASTUZUMAB DERUXTECAN-NXKI
 Breast Cancer 3.8% 82.3%
78.4–85.6%
 1.00 2023 (n=64) 56% ▸
POHERDY
PERTUZUMAB-DPZB
 Breast Cancer 3.8% 82.3%
77.6–86.0%
 1.00 2023 (n=64) 56% ▸
PHESGO
PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF
 Breast Cancer 3.8% 82.3%
78.9–85.7%
 1.00 2023 (n=64) 56% ▸
VEGZELMA
BEVACIZUMAB-ADCD
 Breast Cancer 3.8% 82.3%
78.4–85.6%
 1.00 2023 (n=64) 56% ▸
MVASI
BEVACIZUMAB-AWWB
 Breast Cancer 3.8% 82.3%
78.0–85.8%
 1.00 2023 (n=64) 56% ▸
ZIRABEV
BEVACIZUMAB-BVZR
 Breast Cancer 3.8% 82.3%
78.2–85.7%
 1.00 2023 (n=64) 56% ▸
JOBEVNE
BEVACIZUMAB-NWGD
 Breast Cancer 3.8% 82.3%
78.6–85.7%
 1.00 2023 (n=64) 56% ▸
AVZIVI
BEVACIZUMAB-TNJN
 Breast Cancer 3.8% 82.3%
78.8–85.8%
 1.00 2023 (n=64) 56% ▸
ALYMSYS
BEVACIZUMAB-MALY
 Breast Cancer 3.8% 82.3%
79.0–85.5%
 1.00 2023 (n=64) 56% ▸
KISQALI FEMARA CO-PACK (COPACKAGED)
LETROZOLE
 Breast Cancer 3.8% 82.3%
78.3–85.3%
 1.00 2023 (n=64) 56% ▸
KISQALI
RIBOCICLIB SUCCINATE
 Breast Cancer 3.8% 82.3%
78.3–86.1%
 1.00 2023 (n=64) 56% ▸
PERJETA
PERTUZUMAB
 Breast Cancer 80.2% 79.6%
75.7–83.3%
 1.00 2023 (n=64) 56% ▸
TECENTRIQ HYBREZA
ATEZOLIZUMAB AND HYALURONIDASE-TQJS
 Non-Small Cell Lung Cancer 5.6% 76.4%
71.0–80.9%
 1.01 2020 (n=46) 56% ▸
VEGZELMA
BEVACIZUMAB-ADCD
 Non-Small Cell Lung Cancer 5.6% 76.4%
70.8–80.6%
 1.01 2020 (n=46) 56% ▸
MVASI
BEVACIZUMAB-AWWB
 Non-Small Cell Lung Cancer 5.6% 76.4%
71.6–80.4%
 1.01 2020 (n=46) 56% ▸
ZIRABEV
BEVACIZUMAB-BVZR
 Non-Small Cell Lung Cancer 5.6% 76.4%
72.1–80.8%
 1.01 2020 (n=46) 56% ▸
JOBEVNE
BEVACIZUMAB-NWGD
 Non-Small Cell Lung Cancer 5.6% 76.4%
70.6–80.2%
 1.01 2020 (n=46) 56% ▸
AVZIVI
BEVACIZUMAB-TNJN
 Non-Small Cell Lung Cancer 5.6% 76.4%
71.8–80.5%
 1.01 2020 (n=46) 56% ▸
ALYMSYS
BEVACIZUMAB-MALY
 Non-Small Cell Lung Cancer 5.6% 76.4%
71.6–80.8%
 1.01 2020 (n=46) 56% ▸
TAGRISSO
OSIMERTINIB MESYLATE
 Non-Small Cell Lung Cancer 5.6% 76.4%
72.2–81.1%
 1.01 2020 (n=46) 56% ▸
ALECENSA
ALECTINIB HYDROCHLORIDE
 Non-Small Cell Lung Cancer 5.6% 76.4%
72.2–80.2%
 1.01 2020 (n=46) 56% ▸
YERVOY
IPILIMUMAB
 Colorectal Cancer 6.9% 75.9%
71.1–80.2%
 1.01 2022 (n=44) 56% ▸
VEGZELMA
BEVACIZUMAB-ADCD
 Colorectal Cancer 6.9% 75.9%
70.9–80.5%
 1.01 2022 (n=44) 56% ▸
MVASI
BEVACIZUMAB-AWWB
 Colorectal Cancer 6.9% 75.9%
70.5–79.7%
 1.01 2022 (n=44) 56% ▸
ZIRABEV
BEVACIZUMAB-BVZR
 Colorectal Cancer 6.9% 75.9%
71.9–80.3%
 1.01 2022 (n=44) 56% ▸
JOBEVNE
BEVACIZUMAB-NWGD
 Colorectal Cancer 6.9% 75.9%
70.9–80.3%
 1.01 2022 (n=44) 56% ▸
AVZIVI
BEVACIZUMAB-TNJN
 Colorectal Cancer 6.9% 75.9%
70.8–80.3%
 1.01 2022 (n=44) 56% ▸
ALYMSYS
BEVACIZUMAB-MALY
 Colorectal Cancer 6.9% 75.9%
70.5–79.9%
 1.01 2022 (n=44) 56% ▸
KADCYLA
ADO-TRASTUZUMAB EMTANSINE
 Gastric Cancer 3.9% 75.7%
70.6–80.3%
 1.01 2022 (n=62) 56% ▸
KANJINTI
TRASTUZUMAB-ANNS
 Gastric Cancer 3.9% 75.7%
70.7–80.2%
 1.01 2022 (n=62) 56% ▸
OGIVRI
TRASTUZUMAB-DKST
 Gastric Cancer 3.9% 75.7%
70.0–80.3%
 1.01 2022 (n=62) 56% ▸
TRAZIMERA
TRASTUZUMAB-QYYP
 Gastric Cancer 3.9% 75.7%
70.6–79.7%
 1.01 2022 (n=62) 56% ▸
HERCESSI
TRASTUZUMAB-STRF
 Gastric Cancer 3.9% 75.7%
70.2–81.0%
 1.01 2022 (n=62) 56% ▸
HERZUMA
TRASTUZUMAB-PKRB
 Gastric Cancer 3.9% 75.7%
70.6–80.4%
 1.01 2022 (n=62) 56% ▸
ONTRUZANT
TRASTUZUMAB-DTTB
 Gastric Cancer 3.9% 75.7%
70.5–80.3%
 1.01 2022 (n=62) 56% ▸
HERCEPTIN HYLECTA
TRASTUZUMAB AND HYALURONIDASE-OYSK
 Gastric Cancer 3.9% 75.7%
70.4–79.5%
 1.01 2022 (n=62) 56% ▸
ENHERTU
FAM-TRASTUZUMAB DERUXTECAN-NXKI
 Gastric Cancer 3.9% 75.7%
70.6–80.3%
 1.01 2022 (n=62) 56% ▸
VEGZELMA
BEVACIZUMAB-ADCD
 Gastric Cancer 3.9% 75.7%
70.9–80.8%
 1.01 2022 (n=62) 56% ▸
MVASI
BEVACIZUMAB-AWWB
 Gastric Cancer 3.9% 75.7%
70.6–80.0%
 1.01 2022 (n=62) 56% ▸
ZIRABEV
BEVACIZUMAB-BVZR
 Gastric Cancer 3.9% 75.7%
71.0–80.5%
 1.01 2022 (n=62) 56% ▸
JOBEVNE
BEVACIZUMAB-NWGD
 Gastric Cancer 3.9% 75.7%
70.8–79.7%
 1.01 2022 (n=62) 56% ▸
AVZIVI
BEVACIZUMAB-TNJN
 Gastric Cancer 3.9% 75.7%
70.8–80.5%
 1.01 2022 (n=62) 56% ▸
ALYMSYS
BEVACIZUMAB-MALY
 Gastric Cancer 3.9% 75.7%
70.8–79.7%
 1.01 2022 (n=62) 56% ▸
TECENTRIQ HYBREZA
ATEZOLIZUMAB AND HYALURONIDASE-TQJS
 Bladder Cancer 1.5% 75.5%
70.4–79.4%
 1.01 2019 (n=15) 56% ▸
DARZALEX
DARATUMUMAB
 Multiple Myeloma 1.5% 75.5%
70.7–80.2%
 1.01 2022 (n=28) 56% ▸
DARZALEX FASPRO
DARATUMUMAB AND HYALURONIDASE-FIHJ
 Multiple Myeloma 1.5% 75.5%
70.7–80.0%
 1.01 2022 (n=28) 56% ▸
NINLARO
IXAZOMIB CITRATE
 Multiple Myeloma 1.5% 75.5%
70.8–80.5%
 1.01 2022 (n=28) 56% ▸
EMPLICITI
ELOTUZUMAB
 Multiple Myeloma 1.5% 75.5%
70.8–80.6%
 1.01 2022 (n=28) 56% ▸
VEGZELMA
BEVACIZUMAB-ADCD
 Hepatocellular Carcinoma 1.9% 75.3%
70.6–80.0%
 1.01 2022 (n=14) 56% ▸
MVASI
BEVACIZUMAB-AWWB
 Hepatocellular Carcinoma 1.9% 75.3%
70.1–80.0%
 1.01 2022 (n=14) 56% ▸
ZIRABEV
BEVACIZUMAB-BVZR
 Hepatocellular Carcinoma 1.9% 75.3%
70.1–80.1%
 1.01 2022 (n=14) 56% ▸
JOBEVNE
BEVACIZUMAB-NWGD
 Hepatocellular Carcinoma 1.9% 75.3%
69.2–79.4%
 1.01 2022 (n=14) 56% ▸
AVZIVI
BEVACIZUMAB-TNJN
 Hepatocellular Carcinoma 1.9% 75.3%
70.3–79.1%
 1.01 2022 (n=14) 56% ▸
ALYMSYS
BEVACIZUMAB-MALY
 Hepatocellular Carcinoma 1.9% 75.3%
69.6–79.6%
 1.01 2022 (n=14) 56% ▸
YERVOY
IPILIMUMAB
 Melanoma 1.9% 75.0%
69.4–79.2%
 1.01 2024 (n=8) 56% ▸
VEGZELMA
BEVACIZUMAB-ADCD
 Ovarian Cancer 1.8% 74.2%
69.0–79.2%
 1.01 2022 (n=37) 56% ▸
MVASI
BEVACIZUMAB-AWWB
 Ovarian Cancer 1.8% 74.2%
69.2–79.4%
 1.01 2022 (n=37) 56% ▸
ZIRABEV
BEVACIZUMAB-BVZR
 Ovarian Cancer 1.8% 74.2%
69.5–78.7%
 1.01 2022 (n=37) 56% ▸
JOBEVNE
BEVACIZUMAB-NWGD
 Ovarian Cancer 1.8% 74.2%
69.1–78.9%
 1.01 2022 (n=37) 56% ▸
AVZIVI
BEVACIZUMAB-TNJN
 Ovarian Cancer 1.8% 74.2%
68.7–78.5%
 1.01 2022 (n=37) 56% ▸
ALYMSYS
BEVACIZUMAB-MALY
 Ovarian Cancer 1.8% 74.2%
68.9–79.1%
 1.01 2022 (n=37) 56% ▸
YERVOY
IPILIMUMAB
 Renal Cell Carcinoma 1.5% 73.5%
68.2–78.6%
 1.01 2022 (n=13) 56% ▸
VEGZELMA
BEVACIZUMAB-ADCD
 Renal Cell Carcinoma 1.5% 73.5%
68.5–77.6%
 1.01 2022 (n=13) 56% ▸
MVASI
BEVACIZUMAB-AWWB
 Renal Cell Carcinoma 1.5% 73.5%
68.2–78.4%
 1.01 2022 (n=13) 56% ▸
ZIRABEV
BEVACIZUMAB-BVZR
 Renal Cell Carcinoma 1.5% 73.5%
68.0–79.2%
 1.01 2022 (n=13) 56% ▸
JOBEVNE
BEVACIZUMAB-NWGD
 Renal Cell Carcinoma 1.5% 73.5%
68.2–78.0%
 1.01 2022 (n=13) 56% ▸
AVZIVI
BEVACIZUMAB-TNJN
 Renal Cell Carcinoma 1.5% 73.5%
67.8–78.8%
 1.01 2022 (n=13) 56% ▸
ALYMSYS
BEVACIZUMAB-MALY
 Renal Cell Carcinoma 1.5% 73.5%
68.9–78.5%
 1.01 2022 (n=13) 56% ▸
HERCEPTIN
TRASTUZUMAB
 Breast Cancer 84.2% 73.3%
68.4–78.3%
 1.00 2023 (n=64) 56% ▸
TRUXIMA
RITUXIMAB-ABBS
 Diffuse Large B-Cell Lymphoma 0.5% 73.2%
68.3–78.1%
 1.01 2023 (n=15) 56% ▸
RUXIENCE
RITUXIMAB-PVVR
 Diffuse Large B-Cell Lymphoma 0.5% 73.2%
67.7–77.8%
 1.01 2023 (n=15) 56% ▸
RIABNI
RITUXIMAB-ARRX
 Diffuse Large B-Cell Lymphoma 0.5% 73.2%
67.9–77.6%
 1.01 2023 (n=15) 56% ▸
IMFINZI
DURVALUMAB
 Non-Small Cell Lung Cancer 81.7% 73.1%
66.8–77.2%
 1.01 2020 (n=46) 56% ▸
TRUXIMA
RITUXIMAB-ABBS
 Chronic Lymphocytic Leukemia 0.3% 72.9%
67.3–77.4%
 1.01 2023 (n=21) 56% ▸
RUXIENCE
RITUXIMAB-PVVR
 Chronic Lymphocytic Leukemia 0.3% 72.9%
67.6–77.5%
 1.01 2023 (n=21) 56% ▸
RIABNI
RITUXIMAB-ARRX
 Chronic Lymphocytic Leukemia 0.3% 72.9%
67.2–77.6%
 1.01 2023 (n=21) 56% ▸
ERBITUX
CETUXIMAB
 Colorectal Cancer 85.5% 72.5%
66.3–76.8%
 1.01 2022 (n=44) 56% ▸
ERBITUX
CETUXIMAB
 Head and Neck Cancer 89.5% 71.3%
66.2–75.8%
 1.01 2022 (n=25) 56% ▸
HERCEPTIN
TRASTUZUMAB
 Gastric Cancer 87.6% 64.7%
59.5–70.5%
 1.01 2022 (n=62) 56% ▸
Ibrance
 Breast Cancer 2.6% 55.9%
50.0–62.0%
 0.01 2023 (n=64) 56% ▸
Kisqali
 Breast Cancer 2.6% 55.9%
49.2–62.6%
 0.01 2023 (n=64) 56% ▸
Verzenio
 Breast Cancer 2.6% 55.9%
49.8–61.7%
 0.01 2023 (n=64) 56% ▸
Lynparza
 Breast Cancer 2.6% 55.9%
48.1–62.3%
 0.01 2023 (n=64) 56% ▸
Trodelvy
 Breast Cancer 2.6% 55.9%
50.9–62.1%
 0.01 2023 (n=64) 56% ▸
Enhertu
 Breast Cancer 2.6% 55.9%
48.8–61.7%
 0.01 2023 (n=64) 56% ▸
Kadcyla
 Breast Cancer 2.6% 55.9%
49.9–62.2%
 0.01 2023 (n=64) 56% ▸
Keytruda
 Non-Small Cell Lung Cancer 3.4% 46.9%
41.0–52.7%
 0.01 2020 (n=46) 56% ▸
Opdivo
 Non-Small Cell Lung Cancer 3.4% 46.9%
40.4–53.5%
 0.01 2020 (n=46) 56% ▸
Tecentriq
 Non-Small Cell Lung Cancer 3.4% 46.9%
40.8–52.7%
 0.01 2020 (n=46) 56% ▸
Imfinzi
 Non-Small Cell Lung Cancer 3.4% 46.9%
40.0–53.3%
 0.01 2020 (n=46) 56% ▸
Tagrisso
 Non-Small Cell Lung Cancer 3.4% 46.9%
41.2–52.8%
 0.01 2020 (n=46) 56% ▸
Keytruda
 Gastric Cancer 3.2% 45.9%
39.1–52.8%
 0.01 2022 (n=62) 56% ▸
Enhertu
 Gastric Cancer 3.2% 45.9%
40.3–52.0%
 0.01 2022 (n=62) 56% ▸
Keytruda
 Bladder Cancer 0.8% 45.6%
39.5–50.4%
 0.01 2019 (n=15) 56% ▸
Tecentriq
 Bladder Cancer 0.8% 45.6%
39.4–51.9%
 0.01 2019 (n=15) 56% ▸
Darzalex
 Multiple Myeloma 0.8% 45.6%
40.4–52.5%
 0.01 2022 (n=28) 56% ▸
Revlimid
 Multiple Myeloma 0.8% 45.6%
39.7–51.4%
 0.01 2022 (n=28) 56% ▸
Pomalyst
 Multiple Myeloma 0.8% 45.6%
39.4–51.1%
 0.01 2022 (n=28) 56% ▸
Velcade
 Multiple Myeloma 0.8% 45.6%
39.3–51.9%
 0.01 2022 (n=28) 56% ▸
Kyprolis
 Multiple Myeloma 0.8% 45.6%
40.5–51.5%
 0.01 2022 (n=28) 56% ▸
Opdivo
 Hepatocellular Carcinoma 0.7% 45.4%
38.8–51.1%
 0.01 2022 (n=14) 56% ▸
Keytruda
 Melanoma 0.7% 44.9%
40.0–52.0%
 0.01 2024 (n=8) 56% ▸
Opdivo
 Melanoma 0.7% 44.9%
38.8–50.8%
 0.01 2024 (n=8) 56% ▸
Yervoy
 Melanoma 0.7% 44.9%
38.4–50.3%
 0.01 2024 (n=8) 56% ▸
Venclexta
 Acute Myeloid Leukemia 0.7% 44.9%
39.7–50.6%
 0.01 2026 (n=2) 56% ▸
Keytruda
 Head and Neck Cancer 0.5% 44.7%
39.0–52.4%
 0.01 2022 (n=25) 56% ▸
Opdivo
 Head and Neck Cancer 0.5% 44.7%
38.5–50.6%
 0.01 2022 (n=25) 56% ▸
Lynparza
 Ovarian Cancer 0.6% 43.9%
37.5–50.0%
 0.01 2022 (n=37) 56% ▸
Zejula
 Ovarian Cancer 0.6% 43.9%
37.2–50.6%
 0.01 2022 (n=37) 56% ▸
Opdivo
 Renal Cell Carcinoma 0.6% 43.0%
36.7–48.4%
 0.01 2022 (n=13) 56% ▸
Calquence
 Chronic Lymphocytic Leukemia 0.3% 42.2%
36.1–49.5%
 0.01 2023 (n=21) 56% ▸
Imbruvica
 Chronic Lymphocytic Leukemia 0.3% 42.2%
35.4–48.9%
 0.01 2023 (n=21) 56% ▸
Venclexta
 Chronic Lymphocytic Leukemia 0.3% 42.2%
35.9–48.5%
 0.01 2023 (n=21) 56% ▸
Zytiga
 Prostate Cancer 0.0% 42.0%
35.2–49.1%
 0.01 2022 (n=33) 56% ▸
Xtandi
 Prostate Cancer 0.0% 42.0%
36.3–47.9%
 0.01 2022 (n=33) 56% ▸
Nubeqa
 Prostate Cancer 0.0% 42.0%
36.8–49.7%
 0.01 2022 (n=33) 56% ▸
Erleada
 Prostate Cancer 0.0% 42.0%
35.3–48.5%
 0.01 2022 (n=33) 56% ▸
AVASTIN
BEVACIZUMAB
 Breast Cancer 86.2% 6.3%
4.9–8.0%
 1.00 2023 (n=64) 56% ▸
AVASTIN
BEVACIZUMAB
 Non-Small Cell Lung Cancer 81.7% 4.5%
3.3–5.6%
 1.01 2020 (n=46) 56% ▸
AVASTIN
BEVACIZUMAB
 Colorectal Cancer 85.5% 4.4%
3.5–5.4%
 1.01 2022 (n=44) 56% ▸
AVASTIN
BEVACIZUMAB
 Gastric Cancer 87.6% 4.3%
3.5–5.4%
 1.01 2022 (n=62) 56% ▸
AVASTIN
BEVACIZUMAB
 Hepatocellular Carcinoma 85.7% 4.2%
3.3–5.3%
 1.01 2022 (n=14) 56% ▸
AVASTIN
BEVACIZUMAB
 Ovarian Cancer 89.5% 4.0%
3.1–5.0%
 1.01 2022 (n=37) 56% ▸
AVASTIN
BEVACIZUMAB
 Renal Cell Carcinoma 85.2% 3.9%
3.0–4.8%
 1.01 2022 (n=13) 56% ▸